Key Research Presentations at⁢ the European​ Scientific Working Group on Influenza (ESWI)

CSL Seqirus, a global biotechnology company,‍ presented significant new⁣ research findings related to its portfolio‌ of seasonal influenza vaccines at the European Scientific Working Group on Influenza (ESWI) 2025 conference. The presentations covered ⁣a range of ‍topics‌ aimed‍ at ⁢improving influenza prevention strategies⁤ adn vaccine effectiveness.

Focus on Adjuvanted Influenza Vaccines

A core area of ‌research highlighted by CSL Seqirus involved its adjuvanted influenza vaccines (AIV). Data presented demonstrated the⁢ potential of AIVs to elicit a more robust immune response, particularly in older adults-a ⁤demographic frequently enough experiencing‌ reduced⁢ vaccine efficacy with‌ standard influenza vaccines. This ⁣is crucial as individuals aged 65 years and older ⁣account for a disproportionate number of severe influenza-related complications, according ⁣to the Centers for Disease Control and Prevention.

Next-Generation Influenza Vaccines

CSL Seqirus ⁢also⁣ shared updates on its ‍development pipeline for next-generation influenza vaccines. This includes research into novel vaccine candidates designed to⁢ provide broader and more durable protection against ⁣evolving influenza strains. The company’s work⁣ explores innovative‍ approaches to address the challenge of antigenic drift, the continuous mutation ‍of influenza​ viruses that necessitates annual vaccine updates.

Real-World Evidence and Vaccine Effectiveness Studies

Presentations included analyses of real-world data evaluating⁢ the effectiveness of CSL Seqirus’s influenza vaccines in diverse populations. These studies aim to⁢ provide a complete⁢ understanding‌ of vaccine performance under various conditions and inform public health recommendations. Understanding ​real-world effectiveness is vital, as clinical‌ trial results ⁣may not always fully reflect how vaccines perform in ‍broader ‌community settings.

Commitment to Influenza Prevention

These research efforts ⁣underscore CSL Seqirus’s ongoing commitment to advancing‌ influenza prevention globally. By ⁢investing in innovative vaccine technologies and conducting rigorous scientific studies,the company aims to reduce the burden of influenza and protect public health. The ESWI conference serves as a key platform for ⁢sharing these advancements with the scientific ⁢community and ​healthcare professionals.